Literature DB >> 8144509

The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy.

J W Weisel1, C Nagaswami, J L Woodhead, R A DeLa Cadena, J D Page, R W Colman.   

Abstract

Knowledge of the organization of the kininogen gene and protein structure and function correlations has allowed the development of a model of high molecular weight kininogen. Domains 1-3 on the heavy chain are evolutionarily related to cystatin and the latter two are inhibitors of cysteine proteases. Proteolytic cleavage in domain 4 to release bradykinin causes a conformational change, exposing a surface-binding region (domain 5) on the disulfide-linked light chain. The carboxyl-terminal domain 6 contains a zymogen binding sequence for factor XI and prekallikrein which, with domain 5, accounts for its cofactor activity. To explore further the domain structure, we have determined the shapes of high molecular weight kininogen and prekallikrein by electron microscopy of rotary shadowed preparations and computer image processing. High molecular weight kininogen appears to be a linear array of three linked globular regions about 16 nm long, with the two ends also connected by another thin strand. Both prekallikrein and kallikrein have a compact globular shape, with a subdivision that is sometimes visible. Different functional domains of high molecular weight kininogen were identified by monoclonal antibodies against these regions, as well as ligand binding of prekallikrein. These studies indicate that one end globular region is the prekallikrein-binding domain, the other comprises the cysteine protease inhibitor domains and the smaller central nodule is the surface-binding domain. Cleavage of high molecular weight kininogen with plasma kallikrein to yield two-chain high molecular weight kininogen results in a striking change in conformation: the central surface-binding domain swings out so that it is still adjacent to the prekallikrein-binding domain but no longer in the middle. These structural studies provide insight into the interactions of these proteins and aspects of the mechanisms of their actions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8144509

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Solution structure of the A4 domain of factor XI sheds light on the mechanism of zymogen activation.

Authors:  Dharmaraj Samuel; Hong Cheng; Paul W Riley; Adrian A Canutescu; Chandrasekaran Nagaswami; John W Weisel; Zimei Bu; Peter N Walsh; Heinrich Roder
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-20       Impact factor: 11.205

2.  Regulatory effects of ferritin on angiogenesis.

Authors:  Lan G Coffman; Derek Parsonage; Ralph D'Agostino; Frank M Torti; Suzy V Torti
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-06       Impact factor: 11.205

3.  The high-molecular-weight kininogen domain 5 is an intrinsically unstructured protein and its interaction with ferritin is metal mediated.

Authors:  Annissa J Huhn; Derek Parsonage; David A Horita; Frank M Torti; Suzy V Torti; Thomas Hollis
Journal:  Protein Sci       Date:  2014-05-22       Impact factor: 6.725

4.  Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor.

Authors:  R W Colman; R A Pixley; S Najamunnisa; W Yan; J Wang; A Mazar; K R McCrae
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

5.  High-affinity binding of two molecules of cysteine proteinases to low-molecular-weight kininogen.

Authors:  B Turk; V Stoka; I Björk; C Boudier; G Johansson; I Dolenc; A Colic; J G Bieth; V Turk
Journal:  Protein Sci       Date:  1995-09       Impact factor: 6.725

6.  Cleaved high-molecular-weight kininogen accelerates the onset of endothelial progenitor cell senescence by induction of reactive oxygen species.

Authors:  Jihong Dai; Xuemei Zhu; Mervin C Yoder; Yi Wu; Robert W Colman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-01-20       Impact factor: 8.311

7.  A monoclonal antibody to high-molecular weight kininogen is therapeutic in a rodent model of reactive arthritis.

Authors:  Ricardo G Espinola; Audrey Uknis; Irma M Sainz; Irma Isordia-Salas; Robin Pixley; Raul DeLa Cadena; Walter Long; Alexis Agelan; John Gaughan; Albert Adam; Robert W Colman
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

8.  Upregulation of tissue factor in monocytes by cleaved high molecular weight kininogen is dependent on TNF-alpha and IL-1beta.

Authors:  Mohammad M Khan; Yuchuan Liu; Munir E Khan; Megan L Gilman; Sabina T Khan; Michael Bromberg; Robert W Colman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-04       Impact factor: 4.733

9.  Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis.

Authors:  Sergei Merkulov; Wan-Ming Zhang; Anton A Komar; Alvin H Schmaier; Ellen Barnes; Yihua Zhou; Xincheng Lu; Takayuki Iwaki; Francis J Castellino; Guangbin Luo; Keith R McCrae
Journal:  Blood       Date:  2007-11-13       Impact factor: 22.113

10.  Ferritin binds to light chain of human H-kininogen and inhibits kallikrein-mediated bradykinin release.

Authors:  Narayanan Parthasarathy; Suzy V Torti; Frank M Torti
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.